by Jean-Michel Molina, Claire Pintado, Caroline Gatey et al.
BMC Medicine 2013, 11:186 (23 August 2013)

7 pp. 468 kB:
http://www.biomedcentral.com/content/pdf/1741-7015-11-186.pdf

Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals in the USA, there has been much controversy about the implementation of this PrEP regimen in other countries throughout the world, and in Europe in particular. In this review, the authors focus on the challenges and opportunities of a daily oral PrEP regimen to curb the rising incidence of HIV infection in high-risk groups, and particularly in men who have sex with men.

(Visited 13 times, 1 visits today)
This entry was posted in Global Health, HIV - AIDS - STI. Bookmark the permalink.
Facebook Auto Publish Powered By : XYZScripts.com
Get the latest issue of the NewsletterDownload